XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform
HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent...
ImmVira’s MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good safety and tolerability results. Late stage patients with pancreatic, colon, lung, and endometrial cancer have been...
Transplant Connect to Expand Human Biologics Management Software with Investment from InVita Healthcare Technologies
LOS ANGELES, Jan. 19, 2022 /PRNewswire/ -- Transplant Connect, the world's leading software provider for the donation and transplantation field, is pleased to announce an investment from InVita Healthcare Technologies. InVita provides leading chain of custody software for complex medical environments including blood, plasma, tissue, implant, and forensic DNA. This strategic...
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner Survival benefits across all the subgroups including different tumor pathology type and PD-L1 expression levels The National Medical Products...
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondylitis. LNK01001 is a JAK1 selective inhibitor for the treatment of autoimmune diseases. This study is a...
Bill & Melinda Gates Foundation and Wellcome Pledge US$300 Million to CEPI for COVID-19 Pandemic Response and to Accelerate Epidemic Preparedness
The foundations call on world leaders to support the Coalition for Epidemic Preparedness Innovations (CEPI) to help end the COVID-19 crisis, prepare for future pandemics, and address epidemic threats. SEATTLE and LONDON, Jan. 19, 2022 /PRNewswire/ -- Today the Bill & Melinda Gates Foundation and Wellcome each pledged US$150 million for a total of US$300 million to the Coalition for Epidemic Preparedness Innovations (CEPI), a global...
Amcor to report Half Year 2022 results
ZURICH, Jan. 19, 2022 /PRNewswire/ -- Amcor plc (NYSE: AMCR; ASX: AMC) will announce its Half Year 2022 results for the six months ended 31 December 2021 after the US market closes on Tuesday 1 February 2022. A conference call and webcast to discuss the results will be held at 5.30pm US Eastern Standard Time on Tuesday 1 February 2022 /...
CliniSys acquires HORIZON Lab Systems and combines with Sunquest Information Systems to create one of the world’s largest organizations dedicated to diagnostics and laboratory informatics
· Combined group to enable better public health outcomes through innovation in diagnostics and laboratory informatics technology TUCSON, Arizona, Jan. 18, 2022 /PRNewswire/ -- CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world's largest organizations dedicated to diagnostic...
CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market
LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's activated carbon subsidiary, NingGuo ZheWanZhenHua Activated Carbon Industry Co., LTD. ("ZhenHua"). Under the Agreement, the Company...
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody...
